The poster believes Novo Nordisk ($NVO) will experience significant growth, comparing it to AMD's trajectory in the tech sector. This is a speculative bullish thesis with risks including regulatory challenges in pharmaceuticals, competition in the GLP-1 market, and execution risks on pipeline drugs.

Investor believes NVO has hit bottom and is oversold based on low PE ratio, high selling volume, share buybacks, and attractive dividend, betting on recovery with call options. Key risks include timing the bottom incorrectly, further downside movement, and leverage from options positions.

Novo Nordisk is well-positioned for long-term growth despite recent price cuts on Wegovy, which could actually strengthen its competitive moat by pricing out compounders and lower-quality competitors while establishing it as the trusted standard in the obesity market. The company has multiple growth drivers including European expansion, promising pipeline candidates (UBT251, oral Wegovy, oral CagriSema), and the ability to generate stable recurring cash flows to fund innovation.